Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713243 · ClinicalTrials.gov registry record · Phase 2
To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.
A Phase 2 study of Primary Bile Acid Diarrhea, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT02713243 is a Phase 2 study of Primary Bile Acid Diarrhea that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 20 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT02713243, a Phase 2 study of Primary Bile Acid Diarrhea, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine whether LJN452 improves the symptoms of bile acid diarrhea and to assess its safety and tolerability profile in patients with primary bile acid diarrhea (pBAD) to guide decision-making regarding further clinical development in this indication.
Conditions Studied
Interventions
- DRUG LJN452
- DRUG Placebo to LJN452
Study Locations (4)
Other
- Novartis Investigative Site - London
- Novartis Investigative Site - Sheffield
Minnesota
- Novartis Investigative Site - Rochester
Middlesex
- Novartis Investigative Site - Harrow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-01-16 |
| Est. Completion | 2018-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02713243
The ClinicalTrials.gov registry entry for NCT02713243 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Bile Acid Diarrhea appearing as the primary indexed condition, and to 2 interventions - of which LJN452 is the first listed.
NCT02713243 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, Minnesota, Middlesex.
Frequently Asked Questions
What is clinical trial NCT02713243 about?
NCT02713243 is a clinical study titled "To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.". The purpose of this study is to determine whether LJN452 improves the symptoms of bile acid diarrhea and to assess its safety and tolerability profile in patients with primary bile acid diarrhea (pBAD) to guide decision-making regarding further clinical development in this indication.
What is the current status of trial NCT02713243?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-01-16. Estimated completion is 2018-01-25.
What conditions does trial NCT02713243 study?
This clinical trial studies the following conditions: Primary Bile Acid Diarrhea.
What interventions are being tested in trial NCT02713243?
The interventions under investigation include: LJN452 (DRUG), Placebo to LJN452 (DRUG).
Who is sponsoring clinical trial NCT02713243?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02713243 being conducted?
This trial has 4 study locations across Minnesota, Middlesex. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.